Locational and Clinical Varieties of Warthin Tumor: Two Rare Case Presentations.

Ear Nose Throat J

Department of Otorhinolaryngology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.

Published: January 2023

Warthin tumor (WT) is the second most common benign tumor of the parotid gland with male predominance and is seen in the elderly population in the left mandibular and cervical regions. Extraparotid WT rarely presents as a mass in the right cervical region in middle-aged adults. Here, we present two extraordinary cases of WT seen in middle age, both in the right cervical region. The first is a 50-year-old man with an asymptomatic neck mass, and the second is a 60-year-old woman with a fast-growing mass with enhancement in positron emission tomography-computed tomography (PET-CT) with suspicions of malignancy.

Download full-text PDF

Source
http://dx.doi.org/10.1177/01455613221146895DOI Listing

Publication Analysis

Top Keywords

warthin tumor
8
cervical region
8
locational clinical
4
clinical varieties
4
varieties warthin
4
tumor rare
4
rare case
4
case presentations
4
presentations warthin
4
tumor second
4

Similar Publications

Background: The rising incidence of parotid gland tumors, with a focus on pleomorphic adenomas (PMA) and Warthin tumors (WT), necessitates accurate preoperative distinction due to their treatment variability and PMA's malignant potential. Traditional imaging, while valuable, has limited accuracy. This study employs multi-slice computed tomography (MSCT) radiomics coupled with serum alpha-L-fucosidase (AFU) levels to develop a diagnostic model aimed at elevating clinical discernment and precision therapy delivery.

View Article and Find Full Text PDF

High Field MRI in Parotid Gland Tumors: A Diagnostic Algorithm.

Cancers (Basel)

December 2024

Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, Via Caserta 6, 00161 Rome, Italy.

Imaging of parotid tumors is crucial for surgery planning, but it cannot distinguish malignant from benign lesions with absolute reliability. The aim of the study was to establish a diagnostic MRI algorithm to differentiate parotid tumors. A retrospective study was conducted including all patients with parotid tumors, who underwent 3T-MRI and surgery.

View Article and Find Full Text PDF

This study explores the role of irisin and interleukins in parotid tumors by determining the tissue staining intensity of irisin, the salivary and plasma levels of irisin, and the plasma levels of IL-4, IL-6, IL-10 and TNF-alpha in individuals with parotid tumors. Forty-eight patients and forty healthy individuals were included to the study and allocated into four group. Benign Group I (pleomorphic adenoma), Group II (Warthin's tumor), Group III (mucoepidermoid carcinoma) and Group IV (benign parotid control group, healthy control group).

View Article and Find Full Text PDF

A Rare Diagnosis of Parotid Gland Follicular Lymphoma Arising in Warthin Tumor: Case Report and Literature Review.

Medicina (Kaunas)

December 2024

Oral and Maxillofacial Surgery Department, Barzilai University Medical Center, Ben Gurion University of the Negev, Beer Sheva 8443944, Israel.

: A Warthin tumor is a benign salivary gland neoplasm, mostly found in the parotid gland. The number of reported Warthin tumors has increased over the years due to better diagnostic modalities and health system modernization. Warthin tumor rarely transforms into a malignant tumor; in this work, we present all cases reported in the English literature of different types of lymphomas within Warthin tumors.

View Article and Find Full Text PDF

Salivary gland tumors (SGTs) are diverse lesions with varying morphological and clinical characteristics. Limited data exist on the distribution of SGTs in Saudi Arabia. We aimed to fill this gap by examining the distribution of SGTs across four tertiary hospitals in Riyadh.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!